Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Free Cash Flow (2016 - 2024)

Trinity Biotech's Free Cash Flow history spans 16 years, with the latest figure at $3.7 million for Q4 2024.

  • On a quarterly basis, Free Cash Flow rose 567.86% to $3.7 million in Q4 2024 year-over-year; TTM through Dec 2025 was $3.7 million, a 0.0% change, with the full-year FY2025 number at -$5.7 million, down 23.39% from a year prior.
  • Free Cash Flow hit $3.7 million in Q4 2024 for Trinity Biotech, up from $560000.0 in the prior quarter.
  • Over the last five years, Free Cash Flow for TRIB hit a ceiling of $14.8 million in Q4 2020 and a floor of -$4.5 million in Q3 2023.
  • Historically, Free Cash Flow has averaged $2.7 million across 5 years, with a median of $1.3 million in 2021.
  • Biggest five-year swings in Free Cash Flow: crashed 554.96% in 2023 and later soared 567.86% in 2024.
  • Tracing TRIB's Free Cash Flow over 5 years: stood at $14.8 million in 2020, then crashed by 66.99% to $4.9 million in 2021, then plummeted by 43.63% to $2.8 million in 2022, then crashed by 79.72% to $560000.0 in 2023, then soared by 567.86% to $3.7 million in 2024.
  • Business Quant data shows Free Cash Flow for TRIB at $3.7 million in Q4 2024, $560000.0 in Q4 2023, and -$4.5 million in Q3 2023.